Dr. Rubin discusses the three classes of biologic therapies approved for IBD. These therapies, albeit revolutionary for patient care are limited by clearance issues, need for dose escalation, and loss of response. The arrival of small molecule therapies, such as tofacitinib, a JAK inhibitor, signify a shift in treating IBD. Dr. Rubin argues that these agents may be effective for both induction and maintenance, and perhaps in combination with existing therapies as well. To view the video and read the full article click here.